OC
ALLO icon

Oppenheimer & Co’s Allogene Therapeutics ALLO Stock Holding History

Oppenheimer & Co’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.9K Buy
11,500
+1,000
+10% +$2.2K ﹤0.01% 1751
2026
Q1 		$25.6K Buy
+10,500
New +$21K ﹤0.01% 1676
2025
Q4 		– Sell
-10,500
Closed -$13K – 1551
2025
Q3 		$13K Hold
10,500
– – ﹤0.01% 1644
2025
Q2 		$11.9K Hold
10,500
– – ﹤0.01% 1600
2025
Q1 		$15.3K Hold
10,500
– – ﹤0.01% 1558
2024
Q4 		$22.4K Hold
10,500
– – ﹤0.01% 1538
2024
Q3 		$29.4K Hold
10,500
– – ﹤0.01% 1493
2024
Q2 		$24.5K Hold
10,500
– – ﹤0.01% 1416
2024
Q1 		$46.9K Sell
10,500
-1,900
-15% -$7.93K ﹤0.01% 1410
2023
Q4 		$39.8K Hold
12,400
– – ﹤0.01% 1356
2023
Q3 		$39.3K Hold
12,400
– – ﹤0.01% 1350
2023
Q2 		$61.6K Buy
+12,400
New +$67.1K ﹤0.01% 1373
2022
Q4 		– Sell
-11,350
Closed -$123K – 1350
2022
Q3 		$123K Sell
11,350
-5,200
-31% -$70.7K ﹤0.01% 1281
2022
Q2 		$189K Buy
16,550
+1,500
+10% +$13.3K ﹤0.01% 1281
2022
Q1 		$137K Buy
15,050
+3,000
+25% +$31.2K ﹤0.01% 1399
2021
Q4 		$180K Sell
12,050
-1,095
-8% -$19.3K ﹤0.01% 1406
2021
Q3 		$338K Sell
13,145
-1,739
-12% -$41.3K 0.01% 1176
2021
Q2 		$388K Sell
14,884
-10,139
-41% -$289K 0.01% 1130
2021
Q1 		$883K Buy
+25,023
New +$844K 0.02% 749
2020
Q2 		– Sell
-13,300
Closed -$259K – 1257
2020
Q1 		$259K Buy
13,300
+5,500
+71% +$131K 0.01% 949
2019
Q4 		$203K Sell
7,800
-10,900
-58% -$300K 0.01% 1174
2019
Q3 		$510K Buy
18,700
+8,500
+83% +$242K 0.01% 786
2019
Q2 		$274K Buy
+10,200
New +$284K 0.01% 1038

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Oppenheimer & Co's ALLO Position: Q2 2026 in Review

Oppenheimer & Co increased its Allogene Therapeutics (ALLO) stake by 9.5% in Q2 2026, buying an estimated $2.2K and bringing the position to 11,500 shares worth $23.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1751.

Oppenheimer & Co first reported a position in ALLO in Q2 2019 and has held it in 23 quarters since. The position peaked at $883K in Q1 2021. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Oppenheimer & Co held 11,500 shares of Allogene Therapeutics worth $23.9K as of Q2 2026.
  • Oppenheimer & Co bought 1,000 Allogene Therapeutics shares in Q2 2026, an estimated $2.2K.
  • Allogene Therapeutics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1751 holding.
  • Oppenheimer & Co first reported a position in Allogene Therapeutics in Q2 2019 and has held it in 23 quarters since.
  • Oppenheimer & Co's Allogene Therapeutics position peaked at $883K in Q1 2021.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.